Literature DB >> 25628393

Breakpoints and drug exposure are inevitably closely linked.

J W C Alffenaar1, O W Akkerman2, M S Bolhuis3, M J Boeree4, W C M de Lange2, T S van der Werf5.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25628393      PMCID： PMC4335836          DOI： 10.1128/AAC.04485-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.

Authors:  Tawanda Gumbo; Jotam G Pasipanodya; Peter Wash; André Burger; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 2.  Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

Authors:  Jakko van Ingen; Rob E Aarnoutse; Peter R Donald; Andreas H Diacon; Rodney Dawson; Georgette Plemper van Balen; Stephen H Gillespie; Martin J Boeree
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

3.  Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.

Authors:  Jurriaan E M de Steenwinkel; Rob E Aarnoutse; Gerjo J de Knegt; Marian T ten Kate; Marga Teulen; Henri A Verbrugh; Martin J Boeree; Dick van Soolingen; Irma A J M Bakker-Woudenberg
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

4.  Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.

Authors:  K J M Aung; A Van Deun; E Declercq; M R Sarker; P K Das; M A Hossain; H L Rieder
Journal:  Int J Tuberc Lung Dis       Date:  2014-10       Impact factor: 2.373

5.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

7.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Authors:  Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079
  7 in total
  2 in total

1.  Reply to "breakpoints and drug exposure are inevitably closely linked".

Authors:  Tawanda Gumbo; Jotam G Pasipanodya; Peter Wash; André Burger; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2015-02       Impact factor: 5.191

2.  Tackling tuberculosis: Insights from an international TB Summit in London.

Authors:  Arundhati Maitra; Cynthia A Danquah; Francesca Scotti; Tracey K Howard; Tengku K Kamil; Sanjib Bhakta
Journal:  Virulence       Date:  2015-07-07       Impact factor: 5.882
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.